Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Axsome Therapeutics, Inc.

< Previous 1 2 3 Next >
Axsome Therapeutics to Report Second Quarter 2025 Financial Results on August 4
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Tickers AXSM
Axsome Therapeutics to Showcase Its Innovative CNS Pipeline at Upcoming Frontiers in Brain Health R&D Day in New York City on July 21
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Tickers AXSM
Axsome Therapeutics Champions Brain Health During Alzheimer's & Brain Awareness Month
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Tickers AXSM
Axsome Therapeutics to Present Data Spanning the SYMBRAVO® (meloxicam and rizatriptan) Clinical Program at the 67th Annual Scientific Meeting of the American Headache Society (AHS)
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Tickers AXSM
Axsome Therapeutics Proudly Supports Migraine and Headache Awareness Month Alongside the Association of Migraine Disorders
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Tickers AXSM
Axsome Therapeutics Showcases Innovation in Sleep Medicine with Multiple Presentations for AXS-12 and Solriamfetol at SLEEP 2025
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Tickers AXSM
Axsome Therapeutics Announces Availability of SYMBRAVO® (meloxicam and rizatriptan) for the Acute Treatment of Migraine with or without Aura in Adults
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Tickers AXSM
Axsome Therapeutics Provides Update on the New Drug Application (NDA) for AXS-14 for the Management of Fibromyalgia
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Tickers AXSM
Axsome Therapeutics to Participate in Upcoming Investor Conferences
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Tickers AXSM
Axsome Therapeutics Presents Data from Three of Its Innovative Neuroscience Programs at the American Society of Clinical Psychopharmacology (ASCP) 2025 Annual Meeting
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Tickers AXSM
Axsome Therapeutics Settles SUNOSI® (solriamfetol) Patent Litigation with Hetero Labs Ltd.
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Tickers AXSM
Axsome Therapeutics Enters $570 Million Term Loan and Revolving Credit Facility with Blackstone
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Tickers AXSM
Axsome Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Tickers AXSM
Axsome Therapeutics and Mental Health America (MHA) Join Voices to Highlight Mental Health Month
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Tickers AXSM
Axsome Therapeutics to Participate in Upcoming Investor Conferences
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Tickers AXSM
Axsome Therapeutics to Report First Quarter 2025 Financial Results on May 5
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Tickers AXSM
Axsome Therapeutics Presents Positive Pivotal Phase 3 Results of the ACCORD-2 Trial of AXS-05 in Alzheimer’s Disease Agitation and the SYMPHONY Trial of AXS-12 in Narcolepsy at the 2025 American Academy of Neurology (AAN) Annual Meeting
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Tickers AXSM
Axsome Therapeutics Announces Topline Results of PARADIGM Phase 3 Proof-of-Concept Trial of Solriamfetol in Major Depressive Disorder (MDD) with and without Excessive Daytime Sleepiness (EDS)
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Tickers AXSM
Axsome Therapeutics Announces FOCUS Phase 3 Trial of Solriamfetol in Adults with Attention Deficit Hyperactivity Disorder (ADHD) Achieves Primary Endpoint
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Tickers AXSM
Axsome Therapeutics Settles Sunosi® (solriamfetol) Patent Litigation with Hikma Pharmaceuticals USA
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Tickers AXSM
Axsome Therapeutics Announces FDA Pre-NDA Meeting Minutes for AXS-05 in Alzheimer’s Disease Agitation Supporting NDA Submission
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Tickers AXSM
Axsome Therapeutics to Participate in Upcoming Investor Conferences
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Tickers AXSM
Axsome Therapeutics Announces SYMBRAVO® (meloxicam and rizatriptan) Achieves Primary Endpoint in the EMERGE Phase 3 Trial in Migraine Patients Experiencing Inadequate Response to Oral CGRP Inhibitors
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Tickers AXSM
Axsome Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Tickers AXSM
Axsome Therapeutics Announces Settlement Agreement Resolving AUVELITY® (dextromethorphan HBr – bupropion HCl) Patent Litigation
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Tickers AXSM
Axsome Therapeutics Hosts SYMBRAVO® FDA Approval Virtual Investor Event with Expert Thought Leader
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Tickers AXSM
Axsome Therapeutics Announces FDA Approval of SYMBRAVO® (meloxicam and rizatriptan) for the Acute Treatment of Migraine with or without Aura in Adults
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Tickers AXSM
Axsome Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results on February 18
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Tickers AXSM
Axsome Therapeutics Provides Preliminary Fourth Quarter and Full Year 2024 Net Revenue
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Tickers AXSM
Axsome Therapeutics Announces Successful Completion and Results of Phase 3 Clinical Program of AXS-05 in Alzheimer’s Disease Agitation
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Tickers AXSM
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.